We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Critical Final Step in Parthanatos Pathway Identified

By LabMedica International staff writers
Posted on 18 Oct 2016
A team of neurological disease researchers has identified the enzyme responsible for the last link in a chain of molecular steps that constitutes the cell death pathway called parthanatos.

Parthanatos is a form of programmed cell death that is distinct from other cell death processes such as necrosis and apoptosis. More...
While necrosis is caused by acute cell injury resulting in traumatic cell death, and apoptosis is a highly controlled process signaled by apoptotic intracellular signals, parthanatos is caused by the accumulation of PAR (Poly(ADP-ribose)) and the nuclear translocation of apoptosis-inducing factor (AIF) from mitochondria. Parthanatos is also known as PARP-1 dependent cell death. The PARP-1 (Poly(ADP-ribose) polymerase-1) enzyme mediates parthanatos under circumstances in which it becomes over-activated in response to extreme genomic stress and synthesizes PAR, which causes nuclear translocation of AIF. Parthanatos is involved in several well-known diseases including Parkinson’s disease, stroke, heart attack, and diabetes.

Investigators at Johns Hopkins University (Baltimore, MD, USA) reported in the October 7, 2016, issue of the journal Science that they had used two sequential unbiased screens, including a human protein array and a small interfering RNA screen to discover that macrophage migration inhibitory factor (MIF) bound AIF and was required for parthanatos. In the presence of magnesium or calcium ions, MIF possessed both 3′ exonuclease and endonuclease activity. It bound to 5′ unpaired bases of single-stranded DNA with stem loop structure and cleaved its 3′ unpaired bases. These nuclease activities allowed MIF to cleave genomic DNA into large fragments.

Depletion of MIF markedly reduced cell death induced by N-methyl-d-aspartate (NMDA) receptor–activated glutamate toxicity in primary neuronal cultures as well as DNA damage caused by N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) or focal stroke in mice. Mutating key amino acid residues in the nuclease domain of MIF eliminated its nuclease activity and prevented parthanatos. In addition, disrupting the AIF and MIF interaction prevented the translocation of MIF from the cytosol to the nucleus and protected against parthanatos. . Therefore, targeting MIF nuclease activity may offer an important therapeutic opportunity for a variety of disorders with excessive PARP-1 activation.

"We found that AIF binds to MIF and carries it into the nucleus, where MIF chops up DNA," said senior author Dr. Ted Dawson, director of the institute for cell engineering at Johns Hopkins University. "We think that is the final execution step in parthanatos. I cannot overemphasize what an important form of cell death it is; it plays a role in almost all forms of cellular injury. We are interested in finding out whether MIF is also involved in Parkinson's, Alzheimer's, and other neurodegenerative diseases. If so, and if an inhibitor of MIF proves successful in testing, it could have implications for treating many conditions."

Related Links:
Johns Hopkins University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.